Kuros Biosciences Ltd.

As of June 30, 2026, Kuros Bioscience Ltd. carries a market capitalization of 896.06M, placing it among publicly traded companies globally. Its enterprise value stands at 896.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kuros Bioscience Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Kuros Bioscience Ltd. has 39.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Kuros Bioscience Ltd. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Kuros Bioscience Ltd.'s stock has declined approximately 43.13% over the past 52 weeks. The 50-day moving average sits at 32.11, while the 200-day moving average is 24.52.

As of June 30, 2026, Kuros Bioscience Ltd. holds 9.73M in cash and equivalents against 10.07M in total debt, resulting in a net debt position of -9.73M. Total book value stands at 89.26M, with working capital of 38.74M providing operational flexibility.

Kuros Bioscience Ltd.'s most recent stock split took place on October 8, 2020 with a 200:217 split ratio.